Lisdexamfetamine Dimesylate Capsule
Product Images NDC 60687-951

View Photos of Packaging, Regulatory Labels, and Product Appearance

Product Visual Gallery

This gallery contains 19 technical images submitted to the FDA as part of the official labeling for Lisdexamfetamine Dimesylate (NDC 60687-951). Unlike standard consumer photos, these assets often include clinical data figures, molecular chemical structures, and official manufacturer packaging layouts.

As provided by American Health Packaging, these visuals offer a comprehensive scientific overview of the product's physical and chemical identity, aiding pharmacists and researchers in product verification and study.

Product Images & Figures Index

FDA Label Image

20 mg Lisdexamfetamine Capsule Blister.jpg (20 mg Lisdexamfetamine Capsule Blister)

20 mg Lisdexamfetamine Capsule Blister.jpg (20 mg Lisdexamfetamine Capsule Blister)
Packaging labels for LISDEXAMFETAMINE DIMESYLATE 20 mg capsules by American Health Packaging. Each label includes the drug name, dosage strength of 20 mg, barcodes, and placeholders for expiration date and lot number. Labels are arranged in pairs in a grid format.*
FDA Label Image

20 mg Lisdexamfetamine Capsules Carton.jpg (20 mg Lisdexamfetamine Capsules Carton)

20 mg Lisdexamfetamine Capsules Carton.jpg (20 mg Lisdexamfetamine Capsules Carton)
Label for Lisdexamfetamine Dimesylate capsules, 20 mg strength, containing 30 capsules (3 x 10) in a package. The label shows the NDC number 60687-896-21 and specifies the capsules are for oral use and prescription only. It includes a barcode, dosing and storage reminders, distributor information for American Health Packaging, and a QR code for medication guide and prescribing information.*
FDA Label Image

30 mg Lisdexamfetamine Capsule Blister.jpg (30 mg Lisdexamfetamine Capsule Blister)

30 mg Lisdexamfetamine Capsule Blister.jpg (30 mg Lisdexamfetamine Capsule Blister)
Lisdexamfetamine dimesylate 30 mg capsule label from American Health Packaging. The label includes the drug name, strength, dosage form, barcodes, lot number, and expiration date fields. The labels are arranged in pairs on a sheet with identical information repeated.*
FDA Label Image

30 mg Lisdexamfetamine Capsules Carton.jpg (30 mg Lisdexamfetamine Capsules Carton)

30 mg Lisdexamfetamine Capsules Carton.jpg (30 mg Lisdexamfetamine Capsules Carton)
Label for Lisdexamfetamine Dimesylate 30 mg capsules, containing 30 capsules in total (3 bottles of 10 capsules each). The label notes it is a prescription drug (Rx Only) distributed by American Health Packaging, Columbus, Ohio. It includes handling instructions for pharmacists and storage conditions, with a barcode and QR code for medication guide and prescribing information.*
FDA Label Image

40 mg Lisdexamfetamine Capsule Blister.jpg (40 mg Lisdexamfetamine Capsule Blister)

40 mg Lisdexamfetamine Capsule Blister.jpg (40 mg Lisdexamfetamine Capsule Blister)
Label sheet containing multiple identical labels for LISDEXAMFETAMINE DIMESYLATE 40 mg capsules. Each label displays the product name, dosage strength, and dosage form, along with a barcode, expiration date format, and lot number placeholder. The labeler is American Health Packaging, Columbus, Ohio.*
FDA Label Image

40 mg Lisdexamfetamine Capsules Carton.jpg (40 mg Lisdexamfetamine Capsules Carton)

40 mg Lisdexamfetamine Capsules Carton.jpg (40 mg Lisdexamfetamine Capsules Carton)
Label for Lisdexamfetamine Dimesylate capsules, 40 mg strength, containing 30 capsules (3 x 10). The label includes the National Drug Code (NDC) 60687-918-21, states the product is for prescription use only, and provides dosage and storage instructions. It also notes the product is distributed by American Health Packaging in Columbus, Ohio.*
FDA Label Image

50 mg Lisdexamfetamine Capsule Blister.jpg (50 mg Lisdexamfetamine Capsule Blister)

50 mg Lisdexamfetamine Capsule Blister.jpg (50 mg Lisdexamfetamine Capsule Blister)
Lisdexamfetamine dimesylate 50 mg capsules label showing multiple identical labels arranged in a grid. Each label includes the drug name, strength, barcode, lot number, expiration date, and American Health Packaging as the labeler in Ohio. The label format repeats consistently across the sheet.*
FDA Label Image

50 mg Lisdexamfetamine Capsules Carton.jpg (50 mg Lisdexamfetamine Capsules Carton)

50 mg Lisdexamfetamine Capsules Carton.jpg (50 mg Lisdexamfetamine Capsules Carton)
Label for Lisdexamfetamine Dimesylate capsules, 50 mg strength, in a package of 30 capsules (3 bottles of 10). The label includes the NDC 60687-929-21 and indicates the product is Rx only. It is distributed by American Health Packaging and includes dosage form and quantity details, DEA order form requirement, and storage temperature instructions.*
FDA Label Image

60 mg Lisdexamfetamine Capsule Blister.jpg (60 mg Lisdexamfetamine Capsule Blister)

60 mg Lisdexamfetamine Capsule Blister.jpg (60 mg Lisdexamfetamine Capsule Blister)
Sheet of small rectangular labels for Lisdexamfetamine Dimesylate Capsules, 60 mg strength. Each label includes the drug name, dosage form (capsule), strength (60 mg), a barcode, lot number and expiration date placeholders, and the labeler American Health Packaging, Columbus, Ohio.*
FDA Label Image

60 mg Lisdexamfetamine Capsules Carton.jpg (60 mg Lisdexamfetamine Capsules Carton)

60 mg Lisdexamfetamine Capsules Carton.jpg (60 mg Lisdexamfetamine Capsules Carton)
Label for Lisdexamfetamine Dimesylate capsules, 60 mg strength, containing 30 capsules (3 blister packs of 10). The product is presented under American Health Packaging. The label includes dosage warnings, storage conditions, DEA order form requirement, and a QR code for medication guide and prescribing information.*
FDA Label Image

70 mg Lisdexamfetamine Capsule Blister.jpg (70 mg Lisdexamfetamine Capsule Blister)

70 mg Lisdexamfetamine Capsule Blister.jpg (70 mg Lisdexamfetamine Capsule Blister)
Label for LISDEXAMFETAMINE DIMESYLATE 70 mg capsules from American Health Packaging. The label includes the drug name, dosage strength (70 mg), dosage form (capsule), barcode, lot number, expiration date, and manufacturer information, repeated multiple times for packaging purposes.*
FDA Label Image

70 mg Lisdexamfetamine Capsules Carton.jpg (70 mg Lisdexamfetamine Capsules Carton)

70 mg Lisdexamfetamine Capsules Carton.jpg (70 mg Lisdexamfetamine Capsules Carton)
This image shows a dual-panel drug label for Lisdexamfetamine Dimesylate 70 mg capsules. Each panel features dosage form, strength, quantity (30 capsules, 3x10), and Rx Only status. It includes pharmacist dispensing instructions, capsule content details, dosage conditions, DEA order form requirement, tamper protection warning, distributor info (American Health Packaging), and a QR code for medication guide and prescribing info.*
FDA Label Image

Figure 1 (Figure 1)

Figure 1 (Figure 1)
A pharmacokinetic (PK) plot showing fold change and 90% confidence intervals for Cmax and AUC in special populations by gender, age groups (65-74 years, >=75 years), and renal impairment levels (mild, moderate, severe, end stage renal disease). The x-axis represents change relative to reference from 0 to 2.5, with data points displayed as orange diamonds and vertical error bars.*
FDA Label Image

Figure 2 (Figure 2)

Figure 2 (Figure 2)
A horizontal dot plot illustrating the pharmacokinetic (PK) fold change and 90% confidence intervals for Cmax and AUC of Guanfacine, Venlafaxine, and Omeprazole relative to reference. The x-axis shows change relative to reference from 0.0 to 2.0, with data points clustered near 1.0 for all drugs and parameters.*
FDA Label Image

Figure 3 (Figure 3)

Figure 3 (Figure 3)
A scatter plot showing the fold change and 90% confidence intervals in pharmacokinetic parameters (Cmax and AUC) for various interacting drugs with Lisdexamfetamine dimesylate. The drugs listed include Guanfacine, Venlafaxine, caffeine (CYP1A2 substrate), dextromethorphan (CYP2D6 substrate), omeprazole (CYP2C19 substrate), and midazolam (CYP3A substrate). The x-axis represents change relative to reference from 0.0 to 2.0, with most points near 1.0 indicating minimal interaction.*
FDA Label Image

Figure 5&6 (Figure 5)

Figure 5&6 (Figure 5)
Two charts related to lisdexamfetamine dimesylate capsules. The first is a Kaplan-Meier curve showing estimated treatment failure proportion over 50 days in pediatric patients aged 6 to 17, comparing lisdexamfetamine dimesylate capsules and placebo. The second chart displays LS mean PERMP total scores over 14 hours post-dose in adults aged 18 to 55 with ADHD, comparing lisdexamfetamine dimesylate capsules and placebo, with higher scores indicating less severe symptoms.*
FDA Label Image

Figure 7 (Figure 7)

Figure 7 (Figure 7)
A Kaplan-Meier survival curve showing the estimated proportion of subjects with relapse in adults with ADHD over time (days after randomization). The graph compares relapse rates between placebo and lisdexamfetamine dimesylate capsules, with the placebo group showing a higher proportion of relapse over time compared to the lisdexamfetamine dimesylate group.*
FDA Label Image

Figure 8 (Figure 8)

Figure 8 (Figure 8)
Kaplan-Meier survival curve graph depicting estimated proportions of adult subjects with relapse in a study of binge eating disorder (BED). The graph compares relapse over time (days after randomization) between subjects treated with lisdexamfetamine dimesylate capsules and those on placebo, showing proportion of subjects with relapse on the y-axis and time on the x-axis.*
FDA Label Image

Structure (Structural Formula)

Structure (Structural Formula)
Chemical structure of lisdexamfetamine dimesylate, the active ingredient in the prescription drug LISDEXAMFETAMINE DIMESYLATE. The diagram depicts the molecular formula with functional groups and chemical bonds clearly illustrated.*

* About these descriptions: Image descriptions on this page are generated by automated AI analysis of the product label images from the manufacturer's FDA label submission (SPL). They are provided for reference only and may contain errors or omissions. Always rely on the printed label itself and the official FDA labeling, and consult a pharmacist or healthcare professional with any questions about this product.